PL1863905T3 - Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro - Google Patents

Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro

Info

Publication number
PL1863905T3
PL1863905T3 PL06726410T PL06726410T PL1863905T3 PL 1863905 T3 PL1863905 T3 PL 1863905T3 PL 06726410 T PL06726410 T PL 06726410T PL 06726410 T PL06726410 T PL 06726410T PL 1863905 T3 PL1863905 T3 PL 1863905T3
Authority
PL
Poland
Prior art keywords
tumor cell
natural killer
killer cells
cell preparations
vitro tumor
Prior art date
Application number
PL06726410T
Other languages
English (en)
Polish (pl)
Inventor
Mark W Lowdell
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505508A external-priority patent/GB0505508D0/en
Priority claimed from GB0514288A external-priority patent/GB0514288D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of PL1863905T3 publication Critical patent/PL1863905T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL06726410T 2005-03-17 2006-03-16 Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro PL1863905T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0505508A GB0505508D0 (en) 2005-03-17 2005-03-17 Method
GB0514288A GB0514288D0 (en) 2005-07-12 2005-07-12 Method
EP06726410.1A EP1863905B1 (en) 2005-03-17 2006-03-16 Method for activating natural killer cells by tumour cell preparations in vitro
PCT/GB2006/000960 WO2006097743A2 (en) 2005-03-17 2006-03-16 Method for actvating natural killer cells by tumor cell preparation in vitro

Publications (1)

Publication Number Publication Date
PL1863905T3 true PL1863905T3 (pl) 2016-07-29

Family

ID=36992099

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06726410T PL1863905T3 (pl) 2005-03-17 2006-03-16 Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro

Country Status (9)

Country Link
US (3) US8257970B2 (enExample)
EP (2) EP2399594B1 (enExample)
JP (3) JP5663135B2 (enExample)
AU (1) AU2006224313B2 (enExample)
CA (1) CA2601197C (enExample)
DK (1) DK1863905T3 (enExample)
ES (1) ES2566335T3 (enExample)
PL (1) PL1863905T3 (enExample)
WO (1) WO2006097743A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712258B1 (en) 2006-04-14 2025-01-01 Astellas Institute for Regenerative Medicine Hemangio-colony forming cells
BRPI0913108A2 (pt) * 2008-05-29 2017-06-20 Trangene S A método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso de níveis de células exterminadores naturais ativadas como um biomarcador, e, kit
WO2011004201A1 (en) * 2009-07-10 2011-01-13 Mark Lowdell Preserved compositions of activated nk cells and methods of using the same
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
KR102108245B1 (ko) 2011-11-30 2020-05-08 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
WO2013132256A1 (en) 2012-03-07 2013-09-12 Ucl Business Plc Compositions and methods for treating viral-mediated infection and disease in immunocompromised individuals
US9938498B2 (en) 2012-05-07 2018-04-10 Nkmax Co., Ltd. Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
WO2013168978A1 (ko) * 2012-05-07 2013-11-14 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
EP3973967A1 (en) 2012-12-21 2022-03-30 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US10961506B2 (en) * 2014-09-04 2021-03-30 Stemcell Technologies Inc. Soluble antibody complexes for T cell or NK cell activation and expansion
US10758567B2 (en) * 2015-09-16 2020-09-01 Immune Ventures LLC In vivo priming of natural killer cells
JP6850297B2 (ja) * 2015-12-07 2021-03-31 イミューン ベンチャーズ, リミテッド ライアビリティ カンパニーImmune Ventures, Llc ナチュラルキラー細胞の生体内プライミング
CN110582565A (zh) * 2017-03-15 2019-12-17 免疫创业投资有限责任公司 自然杀伤细胞的体内致敏
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
CN112888445B (zh) * 2018-08-30 2025-06-10 免疫生物公司 治疗老年化相关病症的方法
NZ772550A (en) 2018-08-30 2025-08-29 Immunitybio Inc Multi-chain chimeric polypeptides and uses thereof
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
KR20220035394A (ko) * 2019-06-21 2022-03-22 에이치씨더블유 바이올로직스, 인크. 다중-사슬 키메라 폴리펩티드 및 이의 용도
WO2021163298A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20250118299A (ko) * 2024-01-29 2025-08-06 인하대학교 산학협력단 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007630B1 (en) * 1997-04-30 2006-04-19 Hans Klingemann Natural killer cell lines and methods of use
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell

Also Published As

Publication number Publication date
EP2399594B1 (en) 2019-08-14
US9655925B2 (en) 2017-05-23
AU2006224313A1 (en) 2006-09-21
US20140079678A1 (en) 2014-03-20
EP1863905B1 (en) 2016-01-20
JP5663135B2 (ja) 2015-02-04
US8257970B2 (en) 2012-09-04
CA2601197C (en) 2017-06-06
US8637308B2 (en) 2014-01-28
JP2013009686A (ja) 2013-01-17
WO2006097743A2 (en) 2006-09-21
US20120328587A1 (en) 2012-12-27
ES2566335T3 (es) 2016-04-12
WO2006097743A3 (en) 2006-12-14
JP2015012876A (ja) 2015-01-22
JP2008536487A (ja) 2008-09-11
JP5906168B2 (ja) 2016-04-20
EP2399594A1 (en) 2011-12-28
EP1863905A2 (en) 2007-12-12
CA2601197A1 (en) 2006-09-21
HK1112483A1 (zh) 2008-09-05
DK1863905T3 (en) 2016-04-04
AU2006224313B2 (en) 2011-08-11
US20080166326A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
PL1863905T3 (pl) Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro
IL259642B (en) Methods for enhancing natural killer cell proliferation and activity
SI1926813T2 (sl) Celična populacija z imunoregulatorno aktivnostjo, postopek za izolacijo in uporabe
PL2921500T3 (pl) Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
ZA200900905B (en) Modified-galactosyl ceramides for staining and stimulating Natural Killer T cells
IS8619A (is) Ræktun mannafósturstofnfrumna
IL221384A0 (en) Improving il-15 and il-15r-alpha for expression in mammalian cells
PL2257155T3 (pl) Krioprezerwacja komórek i tkanek biologicznych
DK2016089T3 (da) Gendefekter og mutant-alk-kinase i humane faste tumorer
IL189079A0 (en) Method of encapsulating therapeutic substances in cells
SI3620171T1 (sl) Protitelesa proti GM-CSF in uporabe zanje
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
IL201720A0 (en) Use of low temperature and/or low ph in cell culture
SI2132562T1 (sl) Metode za ovrednotenje celic in celičnih kultur
EP1882736A4 (en) CELL CULTURE CONTAINER
DE602005017745D1 (de) Brennstoffzellen-auseinanderbauverfahren
GB0509748D0 (en) Materials and methods relating to cell based therapies
GB2453661B (en) In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells
PL1835022T3 (pl) Sposób hodowli komórek i jego zastosowanie
EP2043677A4 (en) COMBINATIONS OF HUMAN PROTEINS TO INCREASE THE VITABILITY OF STEM CELLS AND PRECURSOR CELLS
EP2029724A4 (en) DERIVATION FROM EMBRYONAL STEM CELLS AND EMBRYO-DERIVED CELLS
PL1945673T3 (pl) Ukierunkowywanie i śledzenie antygenów w żywych komórkach
IL184261A0 (en) Methods for supporting and producing human cells and tissues in non-human mammal hosts
DE602006020005D1 (de) Elektrochemische Zellenstruktur und dessen Herstellung
ZA201101137B (en) Prf in cell and tissue culture